June 16, 2020
June 16, 2020 – The U.S. FDA has approved an expanded indication for Ilaris® (canakinumab), manufactured by Novartis. The product is now indicated to treat active
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Pharmacy Benefits Management
June 16, 2020
June 16, 2020 – The U.S. FDA has approved a new indication for Cosentyx® (secukinumab), manufactured
by Novartis, to treat adults who have active non-radiographic axial
June 16, 2020
June 16, 2020 – The U.S. FDA has approved an expanded indication for Pfizer’s MylotargTM (gemtuzumab
ozogamicin) intravenous injection. Mylotarg is now indicated to treat newly
June 15, 2020
June 15, 2020 – The U.S. FDA has approved Eli Lilly’s LyumjevTM (insulin lispro-aabc injection), a new rapid-
acting human insulin analog, to improve glycemic control in adults
June 15, 2020
June 15, 2020
June 15, 2020 – The U.S. FDA has approved ZepzelcaTM (lurbinectedin), manufactured by PharmaMar and
Jazz Pharmaceuticals, to treat adult patients who have metastatic small cell
June 15, 2020
June 15, 2020 – The U.S. FDA has approved a new indication for Juvéderm® VolumaTM XC (hyaluronic acid),
manufactured by Allergan Aesthetics, for augmentation of the chin region
June 15, 2020
June 15, 2020 – The U.S. FDA has revoked its Emergency Use Authorization (EUA) for oral formulations of
chloroquine and hydroxychloroquine to be used as potential treatments for COVID-19